Prescriber Criteria Form

Lytgobi 2025 PA Fax 5648-A v1 010125.docx Lytgobi (futibatinib) Coverage Determination

This fax machine is located in a secure location as required by HIPAA regulations.

Complete/review information, sign and date. Fax signed forms to CVS Caremark at **1-855-633-7673.** Please contact CVS Caremark at **1-866-785-5714** with questions regarding the prior authorization process. When conditions are met, we will authorize the coverage of Lytgobi (futibatinib).

Drug Name:

Patient ID: Patient DOB: Patient Phone: Prescriber Name: Prescriber Address: City: State: Prescriber Phone: Prescriber Fax: Diagnosis: ICD Code(s): Please circle the appropriate answer for each question. Does the patient have a diagnosis of unresectable, locally advacholangiocarcinoma? [If no, then no further questions.] Has the patient received a previous treatment? [If no, then no further questions.] Does the patient's disease have a fibroblast growth factor receivation or other rearrangement?	Zip:	Yes	No
Prescriber Address: City: State: Prescriber Phone: Prescriber Fax: Diagnosis: ICD Code(s): Please circle the appropriate answer for each question. 1 Does the patient have a diagnosis of unresectable, locally advacholangiocarcinoma? [If no, then no further questions.] 2 Has the patient received a previous treatment? [If no, then no further questions.] 3 Does the patient's disease have a fibroblast growth factor received.		Yes	No
Prescriber Address: City: State: Prescriber Phone: Prescriber Fax: Diagnosis: ICD Code(s): Please circle the appropriate answer for each question. 1 Does the patient have a diagnosis of unresectable, locally advacholangiocarcinoma? [If no, then no further questions.] 2 Has the patient received a previous treatment? [If no, then no further questions.] 3 Does the patient's disease have a fibroblast growth factor received.		Yes	No
Prescriber Phone: Prescriber Phone: Prescriber Fax: Diagnosis: Please circle the appropriate answer for each question. Does the patient have a diagnosis of unresectable, locally advacholangiocarcinoma? [If no, then no further questions.] Has the patient received a previous treatment? [If no, then no further questions.] Does the patient's disease have a fibroblast growth factor received.		Yes	No
Prescriber Phone: Diagnosis: Please circle the appropriate answer for each question. Does the patient have a diagnosis of unresectable, locally adversed to the cholangiocarcinoma? [If no, then no further questions.] Has the patient received a previous treatment? [If no, then no further questions.] Does the patient's disease have a fibroblast growth factor received.		Yes	No
Please circle the appropriate answer for each question. 1 Does the patient have a diagnosis of unresectable, locally adversed to the cholangiocarcinoma? [If no, then no further questions.] 2 Has the patient received a previous treatment? [If no, then no further questions.] 3 Does the patient's disease have a fibroblast growth factor received.	nced or metastatic	Yes	No
Please circle the appropriate answer for each question. Does the patient have a diagnosis of unresectable, locally adversed any cholangiocarcinoma? [If no, then no further questions.] Has the patient received a previous treatment? [If no, then no further questions.] Does the patient's disease have a fibroblast growth factor received.	nced or metastatic	Yes	No
Please circle the appropriate answer for each question. Does the patient have a diagnosis of unresectable, locally adversed any cholangiocarcinoma? [If no, then no further questions.] Has the patient received a previous treatment? [If no, then no further questions.] Does the patient's disease have a fibroblast growth factor received.	anced or metastatic	Yes	No
	otor 2 (FGFR2) gene	Yes	No No
Comments: By signing this form, I attest that the information provided is accurate and documentation supporting this information is available for review if reque		that the	